cellvie is pioneering Therapeutic Mitochondria Transplantation, a novel treatment approach aimed at the cellular energy metabolism. The first application will be in ischemia-reperfusion injury, specifically in kidney transplantation and heart attack patients, with the aim to develop a broad platform
Products, services, technology
cellvie is pioneering Therapeutic Mitochondria Transplantation. The modality being used are mitochondria, the powerhouses of the cell. They are prepared and delivered using proprietary methods and systems, in order to re-invigorate the cell energy metabolism - e.g. in ischemia-distressed cells.
Cooperation possibilities
cellvie is open to collaborations in the field of Therapeutic Mitochondria Transplantation. These may include partnerships for co-development as well as licensing deals.
- https://www.cellvie.bio
- +41 44 591 89 21
- Send an email
- Alexander Schueller
Some insights
Ischemia-reperfusion injury is a leading cause of death worldwide. Medical conditions include heart attacks, strokes, and organ transplantation. Mitochondria transplantation may be the first therapy addressing the root cause of the disease pathology: the disturbed mitochondrial energy metabolism.
We are developing what may be a new therapeutic modality, with the potential to affect to date intractable diseases.
